Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

88
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
88
Electrophilic Aromatic Substitution: Fluorination and Iodination of Benzene01:13

Electrophilic Aromatic Substitution: Fluorination and Iodination of Benzene

7.0K
Bromination and chlorination of aromatic rings by electrophilic aromatic substitution reactions are easily achieved, but fluorination and iodination are difficult to achieve. Fluorine is so reactive that its reaction with benzene is difficult to control, resulting in poor yields of monofluoroaromatic products. To address this, Selectfluor reagent is used as a fluorine source in which a fluorine atom is bonded to a positively charged nitrogen.
7.0K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

299
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
299

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Lenacapavir: First Approval.

Drugs·2023
Same author

Lenacapavir: First Approval.

Drugs·2022
Same author

Correction to: Ozanimod: A Review in Ulcerative Colitis.

Drugs·2022
Same author

Ozanimod: A Review in Ulcerative Colitis.

Drugs·2022
Same author

Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.

Paediatric drugs·2022
Same author

Nivolumab Plus Relatlimab: First Approval.

Drugs·2022
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Nov 28, 2025

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate [18F]SFB
08:33

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate [18F]SFB

Published on: June 28, 2011

13.2K

Sofpironium Bromide: First Approval.

Julia Paik1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|November 25, 2020
PubMed
Summary
This summary is machine-generated.

Sofpironium bromide gel is a new topical anticholinergic treatment for hyperhidrosis. It works by blocking M3 receptors to reduce sweating and gained its first approval in Japan for primary axillary hyperhidrosis.

More Related Videos

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.2K
Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection
09:54

Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection

Published on: February 16, 2020

5.9K

Related Experiment Videos

Last Updated: Nov 28, 2025

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate [18F]SFB
08:33

Microwave-assisted One-pot Synthesis of N-succinimidyl-4-[18F]fluorobenzoate [18F]SFB

Published on: June 28, 2011

13.2K
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
10:33

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

1.2K
Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection
09:54

Synthesis, Characterization, and Application of Superparamagnetic Iron Oxide Nanoprobes for Extrapulmonary Tuberculosis Detection

Published on: February 16, 2020

5.9K

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Hyperhidrosis is a condition characterized by excessive sweating.
  • Topical treatments offer a localized approach to managing hyperhidrosis.
  • Anticholinergic agents can reduce sweat production by blocking specific receptors.

Purpose of the Study:

  • To summarize the development milestones of sofpironium bromide gel.
  • To highlight the drug's approval for treating primary axillary hyperhidrosis (PAH).

Main Methods:

  • Development of a topical anticholinergic agent, sofpironium bromide gel.
  • Inhibition of M3 muscarinic receptors in eccrine glands.
  • Clinical studies to assess safety and efficacy in PAH patients.

Main Results:

  • Sofpironium bromide gel 5% received approval in Japan in September 2020 for PAH.
  • Ongoing clinical trials in the USA are evaluating sofpironium bromide gel 15% for PAH.

Conclusions:

  • Sofpironium bromide gel represents a significant advancement in topical hyperhidrosis treatment.
  • The drug's development pathway demonstrates a targeted approach to managing excessive sweating.